Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 58 of 5804
-
Gene therapy aims to restore sight in rare blindness condition
Disease control OngoingThe objective of this clinical study is to evaluate the safety and efficacy of NR082 in the treatment of LHON caused by mitochondrial ND4 gene mutation. This study will enroll subjects aged ≥ 12 years old and ≤ 75 years old to receive a single bilateral intravitreal (IVT) injecti…
Phase: PHASE3 • Sponsor: Wuhan Neurophth Biotechnology Limited Company • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New weekly shot could reverse liver damage in MASH patients
Disease control Recruiting nowThis study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute …
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New mRNA flu shot shows promise in large trial for older adults
⭐️ VACCINE ⭐️ CompletedThe primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined in…
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 16:46 UTC
-
Triple threat before surgery: new combo aims to crush lung cancer
Disease control Recruiting nowThis is a randomized, controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of SBRT sequencial with Toripalimab and chemotherapy versus Toripalimab and chemotherapy for subjects with resectable, stage II-III NSCLC.
Phase: PHASE3 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
CRISPR gene therapy aims to fix hemophilia b at the DNA level
Disease control Recruiting nowParticipants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called RE…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New hope for rare sarcomas: chemo plus immunotherapy combo enters phase III trial
Disease control Recruiting nowThis phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentia…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Pap test DNA may spot ovarian cancer years before symptoms
Diagnosis Recruiting nowOvarian cancer is the leading cause of death among gynecological malignancies. No screening test is available for this tumor. Serous Tubal Intraepithelial Carcinoma (STIC) is the precursor lesion of the high grade serous ovarian cancer (HGSOC). Preliminary data suggest that tumor…
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
Can reprogrammed immune cells take on hard-to-treat kidney cancer?
⭐️ CURE ⭐️ TerminatedThis is an investigator-initiated trial to evaluate the role of anti-CD70-CAR T cells in locally advanced or recurrent/metastatic renal cell carcinoma that is inoperable.
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: ⭐️ CURE ⭐️
Last updated Jul 25, 2026 00:00 UTC
-
Wearable bracelet could alert stroke patients within 3 hours
Diagnosis Recruiting nowThe aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset. This is a multicenter, prospective observational single-arm trial with a registry-based propen…
Phase: NA • Sponsor: Region Skane • Aim: Diagnosis
Last updated Jul 02, 2026 00:00 UTC
-
One-Time cell therapy could tame tough lupus
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells take on tough leukemias
Disease control Recruiting nowBackground: Chronic lymphocytic leukemia (CLL),small lymphocytic lymphoma (SLL) and B-cell acute lymphoblastic leukemia or lymphoma (ALL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. CD19 is a protein often fou…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Gene-Editing breakthrough? new therapy aims to stop sickle cell pain crises
Disease control Recruiting nowThe goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 injection in treating sickle cell disease.
Phase: EARLY_PHASE1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Landmark trial aims to find best cure for early Voice-Box cancer
⭐️ CURE ⭐️ Recruiting nowThis randomized phase III trial will compare the outcomes of three treatment modalities for early-stage glottic laryngeal cancer (T1-T2N0): transoral CO₂ laser microsurgery (TLM), volumetric modulated arc therapy (VMAT), and MRI-guided stereotactic ablative radiotherapy (MRI-SABR…
Phase: NA • Sponsor: Viktoras Rudzianskas • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 09:02 UTC
-
New drug combo aims to protect kidneys and heart in 11,000-Patient trial
Disease control Recruiting nowThis study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin recepto…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill targets HER2 lung cancer in major trial
Disease control Recruiting nowResearchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tiss…
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
CAR t therapy takes on myasthenia gravis in major new trial
Disease control Recruiting nowA Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis
Phase: PHASE2, PHASE3 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Scientists hunt for hidden genes behind sudden infant death
Knowledge-focused Recruiting nowThis is a multicenter genetic study aimed at identifying new genes/variants associated with sudden infant death syndrome (SIDS) based on whole-genome sequencing of family trios
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New shot could ease bulging eyes in thyroid disease
Disease control OngoingThis is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New cell therapy shows promise in battle against Hard-to-Treat multiple myeloma
Disease control OngoingThe goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and…
Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New hope for kids with aggressive brain cancer: targeted drug combo trial launches
Disease control Recruiting nowThe goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs targe…
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC